VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
This Quarter Return
-7.05%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.34B
AUM Growth
+$1.34B
(+11%)
Cap. Flow
+$216M
Cap. Flow
% of AUM
16.14%
Top 10 Holdings %
Top 10 Hldgs %
54.87%
Holding
79
New
21
Increased
28
Reduced
6
Closed
19
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$69.5M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$42.7M |
| 3 |
Exact Sciences
EXAS
|
$34.9M |
| 4 |
Arcellx
ACLX
|
$31.7M |
| 5 |
Ascendis Pharma
ASND
|
$30.7M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$97.9M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$52.3M |
| 3 |
AstraZeneca
AZN
|
$27.1M |
| 4 |
Atara Biotherapeutics
ATRA
|
$22.8M |
| 5 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$21.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Jazz Pharmaceuticals
JAZZ
$7.75B
| $160M | 11.94% | 1,500,000 +400,000 | +36% | +$42.7M |
|
2
Cytokinetics
CYTK
$4.23B
| $112M | 8.38% | 2,075,000 -75,000 | -3% | -$4.06M |
|
|
3
Ascendis Pharma
ASND
$11.8B
| $102M | 7.63% | 750,000 +225,000 | +43% | +$30.7M |
|
|
4
Ultragenyx Pharmaceutical
RARE
$2.89B
| $74M | 5.52% | 1,800,000 +1,690,000 | +1,536% | +$69.5M |
|
5
Globus Medical
GMED
$8.27B
| $61.6M | 4.6% | 900,000 -100,000 | -10% | -$6.85M |
|
6
Insmed
INSM
$28.8B
| $50.3M | 3.75% | 750,000 | – | – |
|
|
ONC
7
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $49.9M | 3.72% | 350,000 +25,000 | +8% | +$3.57M |
|
8
Soleno Therapeutics
SLNO
$3.6B
| $49M | 3.65% | 1,200,000 -50,000 | -4% | -$2.04M |
|
|
9
Exact Sciences
EXAS
$8.98B
| $39.1M | 2.91% | 925,000 +825,000 | +825% | +$34.9M |
|
|
10
Arcellx
ACLX
$3.85B
| $37.3M | 2.78% | 675,000 +575,000 | +575% | +$31.7M |
|
11
Immatics
IMTX
$619M
| $32M | 2.38% | 2,750,000 +1,550,000 | +129% | +$18M |
|
12
Janux Therapeutics
JANX
$1.37B
| $30.4M | 2.26% | +725,000 | New | +$30.4M |
|
13
Astria Therapeutics
ATXS
$349M
| $29.6M | 2.21% | 3,250,000 +2,150,000 | +195% | +$19.6M |
|
14
KalVista Pharmaceuticals
KALV
$678M
| $27.1M | 2.02% | 2,300,000 +1,645,000 | +251% | +$19.4M |
|
15
Savara
SVRA
$567M
| $26.2M | 1.95% | +6,490,000 | New | +$26.2M |
|
16
iTeos Therapeutics
ITOS
| $26M | 1.94% | +1,750,000 | New | +$26M |
|
17
Applied Therapeutics
APLT
$71M
| $25.4M | 1.89% | 5,430,000 +320,000 | +6% | +$1.49M |
|
18
Axsome Therapeutics
AXSM
$6.05B
| $24.2M | 1.8% | +300,000 | New | +$24.2M |
|
19
Structure Therapeutics
GPCR
$1.11B
| $22M | 1.64% | +560,000 | New | +$22M |
|
20
Liquidia Corp
LQDA
$2.38B
| $22M | 1.64% | 1,830,000 -170,000 | -9% | -$2.04M |
|
21
ALX Oncology
ALXO
$62.7M
| $21.7M | 1.62% | 3,600,000 +990,000 | +38% | +$5.97M |
|
22
uniQure
QURE
$896M
| $21.3M | 1.59% | 4,750,000 +25,000 | +0.5% | +$112K |
|
23
Bristol-Myers Squibb
BMY
$96B
| $20.8M | 1.55% | +500,000 | New | +$20.8M |
|
24
Xenon Pharmaceuticals
XENE
$2.98B
| $20.5M | 1.53% | 525,000 +125,000 | +31% | +$4.87M |
|
25
Praxis Precision Medicines
PRAX
$958M
| $18.2M | 1.36% | 440,000 +230,000 | +110% | +$9.51M |
|